Intellectual Property Prospector

IP Assets Owned by Firms in Transition

April 2, 2007
Volume 2, Number 14

Prospector Profiles in this Issue

Company Name	Reference Number	Category Profile
Acura Pharmaceuticals, Inc.	07.0423	Audit Concerns
Adventrx Pharmaceuticals, Inc.	07.0424	Loss/Deficit
Airnet Communications Corporation	07.0425	IP Asset Sale
Altra Industrial Motion, Inc.	07.0426	Low Rating
Applied Digital Solutions, Inc.	07.0427	Loss/Deficit
Biomoda, Inc.	07.0428	Audit Concerns
BlueGate Corporation	07.0429	Audit Concerns
C2 Global Technologies Inc.	07.0430	Audit Concerns
Calton, Inc.	07.0431	Audit Concerns
Cell Therapeutics, Inc.	07.0432	Loss/Deficit
Clarient, Inc.	07.0433	Loss/Deficit
CPC of America, Inc.	07.0434	Loss/Deficit
Diversa Corporation	07.0435	Audit Concerns
Educate, Inc.	07.0436	Audit Concerns
Endocare, Inc.	07.0437	Audit Concerns
Finlay Fine Jewelry Corporation	07.0438	Low Rating
GeNOsys, Inc.	07.0439	Audit Concerns
Hexion Specialty Chemicals, Inc.	07.0440	Loss/Deficit
InSite Vision, Inc.	07.0441	Audit Concerns
Iron Age Corporation	07.0442	Section 363 Sales
Liquidmetal Technologies, Inc.	07.0443	Audit Concerns
Magna Entertainment Corp.	07.0444	Audit Concerns
MediStem Laboratories, Inc.	07.0445	Audit Concerns
Miracor Diagnostics, Inc.	07.0446	Restructuring
MultiCell Technologies, Inc.	07.0447	Audit Concerns
NBO Systems, Inc.	07.0448	Audit Concerns
Neah Power Systems, Inc.	07.0449	Loss/Deficit
Oragenics, Inc.	07.0450	Audit Concerns
Oscient Pharmaceuticals Corporation	07.0451	Loss/Deficit

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
Pathogenics, Inc.	**07.0452**	Audit Concerns
Pegasus Solutions, Inc.	**07.0453**	Low Rating
Progressive Gaming International Corp.	**07.0454**	Miscellaneous
Protection One, Inc.	**07.0455**	Loss/Deficit
Revlon, Inc.	**07.0456**	Loss/Deficit
Sparta Commercial Services, Inc.	**07.0457**	Loss/Deficit
Steakhouse Partners, Inc.	**07.0458**	Audit Concerns
Sungold International Holdings Corp.	**07.0459**	Audit Concerns
The Allied Defense Group, Inc.	**07.0460**	Audit Concerns
Tweeter Home Entertainment Group, Inc.	**07.0461**	Restructuring
Viewpoint Corporation	**07.0462**	Audit Concerns
Visteon Corporation	**07.0463**	Low Rating
Voice Mobility International, Inc.	**07.0464**	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

Intellectual Property Prospector identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (http://BeardGroup.com). For subscription information call Customer Service at 240-629-3300, ext. 27.

Prospector Profile Selection Criteria:

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

DISCLAIMER: The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

ACCURACY & COVERAGE: The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

SUBSCRIPTIONS: Subscription rate: $575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

Intellectual Property Prospector is a publication **of Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, http://www.beardgroup.com. ISSN 1935-3901. Publisher: Christopher Beard.

Prospector Profile 07.0423

Acura Pharmaceuticals, Inc.

616 N North Ct.
Palatine, IL 60067
(847) 705-7709

NAICS		325412
Employees		13
Revenue	(mil)	$0.00
Income	(mil)	($5.97)
Assets	(mil)	$1.62
Liability	(mil)	$39.90

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: BDO Seidman LLP raised substantial doubt on Acura Pharmaceuticals, Inc.'s ability to continue as a going concern due to its recurring losses from operations and net capital deficiency.

Intellectual Property: The Company has one U.S. patent Notice of Allowance relating to its Aversion® Technology. In addition, the Company has two U.S. non-provisional patent publications, one U.S. non-provisional patent application, one U.S. provisional patent application, and two international patent publications pending relating to its Aversion® Technology. The Company also has seven U.S. issued patents and has one U.S. patent publication pending relating to its Opioid Synthesis Technologies. The Company has retained all of the intellectual property and commercial rights to its Aversion® Technology and related product candidates and its Opioid Synthesis Technologies. [SEC Filing 10-K 03-15-07]

Description: The Company is focused on research and development of an innovative and proprietary abuse-deterrent, abuse-resistant and tamper-resistant platform technology designed to discourage abuse of orally administered pharmaceutical products.

Officers: Andrew D. Reddick (Pres., CEO & Dir.); Ron J. Spivey, Ph.D. (SVP& CSO); Peter A. Clemens, CPA (SVP, CFO & Sec.); James F. Emigh, R.Ph. (VP-Mktg. & Admin); Robert A. Seiser, CPA (VP, Treas. & Controller); Bruce F. Wesson (Dir.); William A. Sumner (Dir.); Richard J. Markham (Dir.); William G. Skelly (Dir.); Immanuel Thangaraj (Dir.)

Auditor: BDO Seidman, LLP

Securities: Common Stock-Symbol ACUR.OB; OTC BB;
331,163,803 common shares outstanding as of March 1, 2007.

Return to top

Prospector Profile 07.0424

Adventrx Pharmaceuticals, Inc.

6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121
(858) 552-0866

NAICS		541710
Employees		20
Revenue	(mil)	$0.00
Income	(mil)	($29.33)
Assets	(mil)	$52.80
Liability	(mil)	$32.84

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Adventrx Pharmaceuticals, Inc. reported a net loss of $29,331,773, higher than the net loss reported in previous years of $24,782,646 in 2005 and $6,701,048 in 2004. As a result of its continuing losses, the Company has an accumulated deficit of $89,296,613 as of December 31, 2006. The Company also used cash for operating activities of $15,773,544 for fiscal year 2006, higher than the $11,646,829 used in 2005 and $5,175,390 used in 2004.

Intellectual Property: The Company owns or has exclusive rights under 12 issued patents and 87 applications pending. Patents and patent applications owned or exclusively licensed include compositions comprising 5,10-methylenetetrahydrofolate and methods of formulation and their use for treating cancer, methods for the production of thiophosphonoformic acid and its analogs and their use for treating HIV, antiviral compositions comprising chitosan and zinc, vinca alkaloid emulsions for treating cancer, paclitaxel and docetaxel emulsions for treating cancer, clarithromycin and vancomycin emulsions for treating bacterial infections, bete-elemene emulsions for treating cancer and other indications, pharmaceutical compositions comprising alpha tocopheryl succinate, and methods for treating drug resistant cancers using organoselenone compounds. The trademark CoFactor is registered in the U.S. Patent and Trademark Office under Registration No. 2,946,934, for use in connection with chemotherapy modulators derived from folic acid. [SEC Filing 10-K 03-15-07]

Description: The Company is engaged in biopharmaceutical research and development. It primarily focuses on new technologies for anticancer and antiviral treatments, which address drug metabolism, toxicity, bioavailability, or resistance problems.

Officers: M. Ross Johnson (Chair); Evan M. Levine (CEO); Gregory P. Hanson (SVP, CFO & Treas.); Alexander J. Denner (Dir.); Mark N.K. Bagnall (Dir.); Michael M. Goldberg (Dir.); Jack Lief (Dir.); Mark J. Pykett (Dir.)

Auditor: J.H. Cohn LLP

Securities: Common Stock-Symbol ANX; AMEX;
89,676,739 common shares outstanding as of March 12, 2007.

Return to top

Prospector Profile 07.0425

Airnet Communications Corporation
3950 Dow Road
Melbourne, FL 32934
(321) 984-1990

NAICS		517212
Employees		102
Revenue	(mil)	$19.64
Income	(mil)	($17.67)
Assets	(mil)	$23.73
Liability	(mil)	$13.01

(for the year ended 12/31/2005)

Category: IP Asset Sale

Event: AirNet Communications Corp. is selling its patents and patent applications in order to satisfy its creditors under a Reorganization Plan approved by the Bankruptcy Court for the Middle District of Florida. The portfolio of 59 issued U.S. patents, 31 issued foreign patents, 7 pending U.S. and 18 pending foreign applications includes seminal SDR Base Station patents dating back to the mid-1990's, and covers a broad-range of hot technologies including solutions for broadband SDR Base Stations, fundamental OFDM and FFT-signal processing techniques, value-added wireless network design, E911 Phase 2-related location services, frequency optimization, and innovative wireless backhaul and power management techniques.

Intellectual Property: The marks AirNet®, AdaptaCell®, AirSite®, Backhaul Free™, RapidCell™, Trip Cap™, SuperCapacity™, IntelliBSS™, iBSS™ and DirectLink™ are trademarks of the Company. As of December 31, 2005, the Company has 58 domestic and 43 foreign patents granted as well as 10 domestic and 16 foreign patent applications pending. One of the issued domestic patents was based on proprietary rights originally obtained from Harris Corporation. The Company signed an agreement granting Motorola the right to obtain a non-exclusive, royalty-free license under any two of its patents. [SEC Filing 10-K 03-28-06]

Description: The Company designs, develops, manufactures and installs broadband, software-defined base stations, base station controllers and related wireless infrastructure components. The Company filed for Chapter 11 protection on May 22, 2006 with the Bankruptcy Court for the Middle District of Florida, case number 06-01171.

Officers: George M. Calhoun (Chair); Glenn A. Ehley (Pres., CEO & Dir.); Joseph F. Gerrity (VP, CFO & Treas.); Terry L. Williams (CTO); Darrell Lance Maynard (Dir.); Gerald Y. Hattori (Dir.); Ronald W. White (Dir.); Daniel A. Saginario (Dir.)

Auditor: BDO Seidman LLP

Attorneys: R. Scott Shuker, Esq. at Latham Shuker Barker Eden & Beaudine LLP; Orlando, FL; (407) 481-5800

Securities: 12,879,290 common shares outstanding as of March 20, 2006.

Return to top

Prospector Profile 07.0426

Altra Industrial Motion, Inc.

14 Hayward Street
Quincy, MA 02171
(617) 328-3300

NAICS		335311
Employees		2,500
Revenue	(mil)	$462.29
Income	(mil)	$10.36
Assets	(mil)	$409.37
Liability	(mil)	$329.85

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service affirmed the 'Caa1' rating on Altra Industrial Motion, Inc.'s 11.25% senior unsecured notes due 2013 with a slight revision on the LGD assessment to LGD6, 91%. The rating outlook was changed to positive. The rating agency also expects material weaknesses in the Company's internal control wherein certain plant locations having encountered difficulty closing their books in a timely and accurate manner in fiscal year 2006.

Intellectual Property: The Company relies on a combination of patents, trademarks, copyright and trade secret laws in the United States and other jurisdictions, as well as employee and third-party non-disclosure agreements, license arrangements and domain name registrations to protect intellectual property. The Company sells its products under a number of registered and unregistered trademarks, which are widely recognized in the industry. With the exception of Boston Gear and Warner Electric, it does not believe any single patent, trademark or trade name is material to its business as a whole. With respect to proprietary know-how, the Company relies on trade secret laws in the United States and other jurisdictions and on confidentiality agreements. Some of its registered and unregistered trademarks include: Warner Electric, Boston Gear, Kilian Manufacturing, Nuttall Gear, Ameridrives, Wichita Clutch, Formsprag Clutch, Bibby Transmissions, Stieber, Matrix International, Inertia Dynamics, Twiflex Limited, Industrial Clutch, Huco Dynatork, Marland Clutch, Delroyd Worm Gear, Warner Linear and Saftek. [SEC Filing 10-K 03-19-07]

Description: The Company designs, produces and markets a wide range of mechanical power transmissions and motion control products serving customers in a diverse group of industries, including energy, general industrial, material handling, mining, and transportation.

Officers: Michael L. Hurt (Chair & CEO); Carl R. Christenson (Pres. & COO); David Wall (CFO); Gerald Ferris (VP- Sales); Timothy McGowan (VP-HR); Craig Schuele (VP-Mktg.)

Auditor: Ernst & Young LLP

Securities: 1,000 common shares outstanding as of March 1, 2007.
9% senior secured notes due December 1, 2011; 11.25% senior notes February 13, 2013.

Return to top

Prospector Profile 07.0427

Applied Digital Solutions, Inc.

1690 South Congress Avenue, Suite 200
Delray Beach, FL 33445
(561) 805-8000

NAICS		541710
Employees		622
Revenue	(mil)	$122.69
Income	(mil)	($27.21)
Assets	(mil)	$171.35
Liability	(mil)	$127.49

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Applied Digital Solutions, Inc. reported a net loss for fiscal year ended December 31, 2006 of $27.209 million, higher than previous years' net loss of $12.212 million in 2005 and $17.299 million in 2004. Net sales increased to $122.688 million in 2006 from $113.737 million in 2005 and $111.999 million in 2004. As a result of its recurring losses, the Company has an accumulated deficit of $468.596 million at December 31, 2006. The Company also has strained liquidity with $50.160 million in total current assets available to pay $54.951 million in total current liabilities.

Intellectual Property: The Company's Healthcare segment patent portfolio consists of six patents issued in the US and Canada. In addition, its Digital Angel subsidiary has eight patents issued in the US and Canada. Its Thermo Life Energy Corp. subdiary was awarded a patent for a low power thermoelectric generator. The Company also has patents relating to its seismic monitoring business and a patent for its interrogator device for reading a plurality of transponders. The Company is also seeking registration of the VeriChip trade name in various product markets in the US and elsewhere in the world. In addition, Thermo Life, Digital Angel and Bio-Thermo are registered trademarks in the US while SARBE has trademark protection in Europe. [SEC Filing 10-K 03-15-07]

Description: The Company engages in the development, marketing, and sale of identification and security products for consumer, commercial, and government sectors worldwide.

Officers: Scott R. Silverman (Chair); Michael E. Krawitz (CEO); Lorraine M. Breece (CFO); J. Michael Norris (Dir.); Daniel E. Penni (Dir.); Dennis G. Rawan (Dir.); Constance K. Weaver (Dir.)

Auditor: Eisner LLP

Securities: Common Stock-Symbol ADSX; NasdaqCM;
66,998,195 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0428

Biomoda, Inc.
8301 Washington Street NE, Suite 6
Albuquerque, NM 87113
(505) 821-0875

NAICS		541710
Employees		3
Revenue	(mil)	$0.00
Income	(mil)	($1.81)
Assets	(mil)	$0.24
Liability	(mil)	$2.11

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Malone & Bailey, PC raised substantial doubt about Biomoda, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company experienced significant losses since inception with no significant revenues. In addition, a significant amount of additional capital will be necessary to advance the development of the Company's products to the point at which they may become commercially viable.

Intellectual Property: The Company licenses a patent from Los Alamos National Laboratories, patent number 5,162,231, for the detection of cancers. The Company owns patent 6,838,248, issued on January 4, 2005, which deals with detecting precancerous conditions in human tissue. It also has patents in six other countries: Australia (670743), Brazil (PI 9106563-1), Canada (2085464), Japan (3,047,468), Korea (171393) and Russia (2114430). These patents protect its rights under U.S. patents 5,162,231 and 5,391,547, and all expire on June 17, 2011. The Company also holds a patent (EPO 533845 B1) from the European Patent Office to protect its rights under U.S. patents 5,162,231 and 5,391,547. [SEC Filing 10-KSB 03-15-07]

Description: The Company focuses on the discovery, development, manufacture, and marketing of medical diagnostic and treatment products used for life threatening and other serious diseases.

Officers: John J. Cousins (Pres., CFO, Treas., Controller & Dir.); Herbert L. Whitaker, Jr. (EVP); Leslie S. Robins (VP, Sec. & Dir.); Jeffrey L Garwin (Dir.)

Auditor: Malone & Bailey, PC

Securities: Common Stock-Symbol BMOD.OB; OTC BB;
9,904,037 common shares outstanding as of March 5, 2007.

Return to top

Prospector Profile 07.0429

BlueGate Corporation

701 North Post Oak Road, Suite 600
Houston, TX 77024
(713) 686-1100

NAICS		561400
Employees		35
Revenue	(mil)	$3.71
Income	(mil)	($9.19)
Assets	(mil)	$0.69
Liability	(mil)	$1.75

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Malone & Bailey PC raised substantial doubt about BlueGate Corporation's ability to continue as a going concern due to its negative working capital and recurring losses from operations.

Intellectual Property: The Company has registered the trademark Medical Grade Network® with the US Patent and Trademark Office. The Company's technology allows hospitals and physicians to achieve physician and clinical integration by communicating in a secure private environment, improving patient care. [SEC Filing 10-KSB 03-15-07]

Description: The Company provides information technology consulting, outsourcing, systems integration, applications development, and managed security solutions for the health care industry.

Officers: William Koehler (Pres. & Dir.); Manfred Sternberg (CEO & Dir.); Charles Leibold (CFO); Stephen Sperco (COO); Richard Yee (SVP-Ops.); Gilbert Gertner (Dir.)

Auditor: Malone & Bailey PC

Securities: Common Stock-Symbol BGAT.OB; OTC BB;
13,078,437 common shares outstanding as of March 2, 2007.

Return to top

Prospector Profile 07.0430

C2 Global Technologies Inc.

40 King St West, Suite 3200
Toronto, Ontario M5H 3Y2
Canada
(416) 866-3000

NAICS		533110
Employees		5
Revenue	(mil)	$0.00
Income	(mil)	($7.68)
Assets	(mil)	$1.39
Liability	(mil)	$1.86

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: BDO Seidman LLP expressed substantial doubt about C2 Global Technologies, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has suffered recurring losses from operations and has a net capital deficiency.

Intellectual Property: In the fourth quarter of 2005, the Company was awarded patents for its VoIP technology from the People's Republic of China and in Canada on October 10, 2006. In the third quarter of 2006, the Company was awarded a patent from Hong Kong, and in the fourth quarter of 2006, the European Patent Office advised that it intends to grant a European patent. In addition, the Company's patent portfolio includes private IP communication network architecture, delay synchronization in compressed audio systems and volume control arrangement for compressed information signals. [SEC Filing 10-K 03-16-07]

Description: The Company engages in the ownership and licensing of patents in voice over internet protocol (VoIP) technology.

Officers: Allan C. Silber (Chair & CEO); Stephen A. Weintraub (EVP, Sec. & Controller); Hal B. Heaton (Dir.); Henry Y.L. Toh (Dir.); Samuel L. Shimer (Dir.)

Auditor: BDO Seidman, LLP

Securities: Common Stock-Symbol COBT.OB; OTC BB;
23,094,850 common shares outstanding as of March 1, 2007.

Return to top

Prospector Profile 07.0431

Calton, Inc.

2050 40th Avenue, Suite One
Vero Beach, FL 32960
(772) 794-1414

NAICS		516110
Employees		10
Revenue	(mil)	$6.63
Income	(mil)	($1.41)
Assets	(mil)	$8.85
Liability	(mil)	$5.82

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Aidman Piser & Company PA expressed substantial doubt about Calton, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditing firm noted that the Company incurred a net loss of approximately $1.4 million during the year ended November 30, 2006 and experienced approximately $5.5 million of negative operating cash flows during that same period. Additionally, the Company had minimal pending homes sales. The Company has approximately $5 million of substantially completed homes in inventory which are the collateral for demand notes payable.

Intellectual Property: On September 5, 2006, the Company's PrivilegeONE Networks LLC subsidiary received a patent for its user rewards program and associated communications systems. PrivilegeONE has also received trademark registrations for "PrivilegeONE" and the PrivilegeONE stylized logo. [SEC Filing 10-KSB 03-15-07]

Description: The Company engages in homebuilding, the provision of Internet business solutions, and the development of a loyalty and co-branded credit card program.

Officers: Anthony J. Caldarone (Chair, Pres. & CEO); Maria F. Caldarone (EVP & Sec.); Laura A. Camisa (SVP, CFO & Treas.)

Auditor: Aidman Piser & Company PA

Securities: Common Stock-Symbol CTON.OB; OTC BB;
9,592,746 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0432

Cell Therapeutics, Inc.
501 Elliott Avenue West, Suite 400
Seattle, WA 98119
(206) 282-7100

NAICS		325412
Employees		214
Revenue	(mil)	$0.08
Income	(mil)	($135.82)
Assets	(mil)	$101.82
Liability	(mil)	$203.43

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Cell Therapeutics Inc.'s balance sheet at Dec. 31, 2006, showed $101.8 million in total assets and $203.4 million in total liabilities, resulting in a $101.6 million total stockholders' deficit. The Company reported a net loss of $35.6 million for the fourth quarter ended Dec. 31, 2006, compared to a net loss of $18.7 million for the same period in 2005. Total revenues for the quarter were $20,000 compared to total revenues of $1.2 million in the fourth quarter of 2005. Total revenues for the year ended Dec. 31, 2006, were $80,000 compared to total revenues of $16.1 million in 2005. For 2006, the Company posted a net loss of $135.8 million, compared to a net loss of $102.5 million in 2005.

Intellectual Property: The Company has exclusive rights to six issued U.S. patents and 126 U.S. and foreign pending or issued patent applications relating to its polymer drug delivery technology. There are six issued U.S. patents, two granted European patents and 72 pending or issued U.S. and foreign patent applications directed to XYOTAX. Of the six issued U.S. patents, two of them and another 20 pending U.S. and foreign patent applications are directed to CT-2106. Additionally, the Company has four issued U.S. patents and 71 foreign pending and issued patents directed to pixantrone. [SEC Filing 10-K 03-16-07]

Description: The Company develops, acquires and commercializes novel treatments for cancer. The Company's research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways to treat cancer.

Officers: James A. Bianco (Pres. & CEO); Louis A. Bianco (EVP); Jade Brown (EVP & Chief Bus. Officer); Jack W. Singer (EVP & Chief Med. Officer); Scott C. Stromatt (EVP); John H. Bauer (Dir.); Vartan Gregorian (Dir.); Mary O. Mundinger (Dir.); Jack W. Singer (Dir.)

Auditor: Stonefield Josephson, Inc.

Securities: Common Stock-Symbol CTIC; NasdaqNM;
109,666,245 common shares outstanding as of July 31, 2006.
5.75% convertible subordinated notes due June 15, 2008; 4% convertible senior subordinated notes due July 1, 2010; 6.75% convertible senior notes due October 31, 2010.

Return to top

Prospector Profile 07.0433

Clarient, Inc.

31 Columbia
Aliso Viejo, CA 92656
(949) 425-5700

NAICS		541710
Employees		204
Revenue	(mil)	$33.60
Income	(mil)	($15.93)
Assets	(mil)	$27.03
Liability	(mil)	$25.87

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Clarient, Inc. posted a net loss of $15,926,000 on revenues of $33,604,000 for the year ended December 31, 2006, as compared with a net loss of $14,802,000 on revenues of $20,149,000 for the same period in 2005. As of December 31, 2006, the Company's balance sheet showed strained liquidity with $11,779,000 in total current assets and $13,723,000 in total current liabilities. The Company's accumulated deficit increased from $120,285,000 in 2005 to $136,211,000 in 2006.

Intellectual Property: The Company's patent approach focuses on broadening the scope of its intellectual property portfolio for laboratory services methodologies, using automated cellular instrumentation, rare event identification, and our proteomic mathematic capabilities. As part of the ACIS Sale, the Company transferred its patent portfolio and other intellectual property relating to its technology business to Zeiss. However, it has retained a license to use certain of the transferred intellectual property, which will be useful in the development of new tests, applications, unique analytical capabilities and other service offerings, including novel markers. The Company also relies on trade secrets and proprietary know-how that are protected, in part, through confidentiality agreements with employees, consultants, customers, business partners, and other third parties. [SEC Filing 10-K 03-27-07]

Description: The Company provides cellular assessment and cancer characterization to community pathologists, academic researchers and university hospitals, and bio-pharmaceutical companies.

Officers: James A. Datin (Chair); Ronald A. Andrews (Pres. & CEO); Heather Creran (EVP & COO); James V. Agnello (SVP & CFO); Peter J. Boni (Dir.); Steven J. Feder (Dir.); Irwin Scher (Dir.); Frank P. Slattery, Jr. (Dir.); Dennis M. Smith (Dir.); Gregory Waller (Dir.); Jon R. Wampler (Dir.)

Auditor: KPMG LLP

Securities: Common Stock Symbol CLRT; NasdaqCM;
71,490,912 common shares outstanding as of March 21, 2007.

Return to top

Prospector Profile 07.0434

CPC of America, Inc.

6336 17th Street Circle East
Sarasota, FL 34243
(941) 727-4370

NAICS		339100
Employees		1
Revenue	(mil)	$0.00
Income	(mil)	($2.81)
Assets	(mil)	$1.74
Liability	(mil)	$2.00

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: CPC of America, Inc. reported a net loss of $2,811,855 for the year ended December 31, 2006, compared to a net loss of $1,625,516 in 2005 and $8,314,255 in 2004. As a result of its recurring losses, the Company has an accumulated deficit of $29,507,092 and stockholder's deficit of $258,652 as of December 31, 2006. The Company also has strained liquidity with only $674,138 in total current assets available to pay $2,000,816 in total current liabilities.

Intellectual Property: The Company holds three patents from the US Patent and Trademark Office for the MedClose device and procedure and a fourth patent is pending. The Company also has applied for a trademark for the name MedClose. In September 2002, the Company received three patents from the U.S. Patent and Trademark Office on its CPCA 2000 counterpulsation unit. At present, it has submitted domestic and international applications to patent the CPCA 2000 and counterpulsation technology and has already received a trademark on the name "CPCA 2000." [SEC Filing 10-K 03-15-07]

Description: The Company engages in the development and acquisition of cardiology medical devices, therapeutic devices, and disposable products.

Officers: Rod A. Shipman (Pres., Sec., Treas. & Dir.); Rafe Cohen (Dir.); William C. Lievense (Dir.)

Auditor: Cacciamata Accountancy Corporation

Securities: Common Stock-Symbol CPCF.OB; OTC BB;
8,520,786 common shares outstanding as of March 13, 2007.

Return to top

Prospector Profile 07.0435

Diversa Corporation

4955 Directors Place
San Diego, CA 92121
(858) 526-5000

NAICS		325199
Employees		287
Revenue	(mil)	$49.20
Income	(mil)	($39.27)
Assets	(mil)	$79.91
Liability	(mil)	$36.99

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP raised substantial doubt about Diversa Corp.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the fiscal years ended December 31, 2006 and 2005. The auditing firm pointed to the Company's insufficient cash and working capital to effect its merger with Celunol Corporation and fund their combined business plan.

Intellectual Property: The Company's intellectual property consists of patents, copyrights, trade secrets, know-how, and trademarks. Protection of intellectual property is a strategic priority for its business. The Company's ability to compete effectively depends on the ability to obtain patents for technologies and products, to maintain trade secrets, to operate without infringing the rights of others, and to prevent others from infringing on proprietary rights. As of December 31, 2006, the Company owned 242 issued patents relating to technologies and had over 500 patents pending. In addition, as of December 31, 2006, the Company had in-licensed over 100 patents or patent applications that strengthen its patent position. The Company also relies on trade secrets, technical know-how, and continuing invention to develop and maintain competitive position. [SEC Filing 10-K 03-16-07]

Description: The Company develops an array of specialty enzymes derived from bio-diverse environments. It customizes enzymes for manufacturers within the alternative fuel, industrial, and health and nutrition markets.

Officers: James H. Cavanaugh (Chair); Edward T. Shonsey (CEO); William H. Baum (EVP-Dev't.); Anthony E. Altig (SVP-Fin. & CFO); Patrick Simms (SVP-Ops.); Jeffrey G. Black (Chief Acctg. Officer); Fernand J. Kaufmann (Dir.); Peter Johnson (Dir.); Mark Leschly (Dir.); Melvin I. Simon (Dir.); Cheryl Wenzinger (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol DVSA; NasdaqGM;
48,350,226 common shares outstanding as of March 1, 2007.
6.99% to 10.43% promissory notes due September 30, 2008 to September 30, 2009.

Return to top

Prospector Profile 07.0436

Educate, Inc.

1001 Fleet Street
Baltimore, MD 21202
(410) 843-8000

NAICS		611710
Employees		10,161
Revenue	(mil)	$354.67
Income	(mil)	($11.89)
Assets	(mil)	$464.78
Liability	(mil)	$259.80

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP expressed substantial doubt on Educate, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The auditing firm stated that the Company did not comply with covenants of loan agreements with a syndicate of banks. Although the Company has obtained a waiver of these defaults as of December 31, 2006, it is likely that the Company will need to obtain additional waivers of these covenants in 2007 to avoid triggering the debt's demand repayment provisions.

Intellectual Property: The Company has federal trademark registrations for the words "Sylvan," "Sylvan Learning Center," "eSylvan", "Hooked on Phonics", "Hooked on Reading" and distinctive logos, along with various other trademarks, patents and service marks. The Company also has applications pending for a number of other distinctive phrases, including "Ace it!," "Catapult Learning," "Hooked on," "Progressus," and "Progressus Therapy, Inc." The Company also has obtained foreign registrations of Sylvan in over 50 countries. The Company has license agreements with franchisees for the right to use certain trademarks and service marks in connection with operation of a franchised learning center subject to certain quality control and other provisions. [SEC Filing 10-K 03-16-07]

Description: The Company is a pre-K-12 education company that provides supplemental education services and products to students and families.

Officers: R. Christopher Hoehn-Saric (Chair & CEO); Peter J. Cohen (Pres. & COO); Kevin E. Shaffer (CFO); C. Alan Schroeder (Gen. Counsel & Sec.); Douglas L. Becker (Dir.); Laurence Berg (Dir.); Michael F. Devine, III (Dir.); David W. Hornbeck (Dir.); Cheryl Krongard (Dir.); Aaron Stone (Dir.); Michael D. Weiner (Dir.); Raul Yzaguirre (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol EEEE; NasdaqGS;
43,163,307 common shares outstanding as of March 5, 2007.
note payable due June 30, 2009; 5.00% to 8.25% notes payable with maturity dates ranging from February 2007 to September 2015.

Return to top

Prospector Profile 07.0437

Endocare, Inc.

201 Technology
Irvine, CA 92618
(949) 450-5400

NAICS		334510
Employees		123
Revenue	(mil)	$27.99
Income	(mil)	($10.77)
Assets	(mil)	$16.25
Liability	(mil)	$11.37

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP expressed substantial doubt on Endocare Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the fiscal years ended December 31, 2006, and 2005. The auditing firm pointed to the Company's recurring operating losses, cash flow deficits, and working capital deficiency.

Intellectual Property: As of December 31, 2006, the Company has rights to 41 issued United States patents relating to cryosurgical ablative technology. Five of the patents are licensed from the owners, while the remainder of the patents are assigned to the Company. Most of these patents relate to cryoprobe technology for creating the freeze zone and precisely controlling the shape of the freeze zone produced by the cryoprobes. Additionally, certain patents relate to computer-guided system for assisting surgeons in properly placing cryoprobes in a patient, a computer-controlled cryosurgery apparatus and method, a cryosurgical integrated control and monitoring system and urethral warming technology. The Company also has rights to 17 pending United States patent applications relative to cryosurgical ablative technology. Additionally, it has rights to 39 foreign patents and pending foreign patent applications in this technology area. The Company sells its products under trademarks and secures trademark protection in the United States and elsewhere. [SEC Filing 10-K 03-16-07]

Description: The Company develops, manufactures, and distributes health care products including its Cryocare and FasTrac systems for the treatment of cancer and other tumors.

Officers: Craig T. Davenport (Chair, Pres., & CEO); Michael R. Rodriguez (SVP-Fin. & CFO); Clint B. Davis (SVP, Sec., & Gen. Counsel); John R. Daniels (Dir.); David L. Goldsmith (Dir.); Eric S. Kentor (Dir.); Terrence A. Noonan (Dir.); Thomas R. Testman (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol ENDO.OB; OTCBB;
31,215,912 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0438

Finlay Fine Jewelry Corporation
529 Fifth Avenue
New York, NY 10017
(212) 808-2800

NAICS		423940
Employees		6,000
Revenue	(mil)	$990.13
Income	(mil)	($55.77)
Assets	(mil)	$520.79
Liability	(mil)	$408.22

(for the year ended 1/28/2006)

Category: Low Rating

Event: Moody's Investors Service downgraded Finlay Fine Jewelry Corp.'s $200 million senior unsecured notes from B3, LGD5, 74%, to Caa1, LGD5, 76%. The rating outlook is negative. Moody's said the downgrade is prompted by the deterioration of the Company's credit metrics as a result of lower expected Holiday sales, additional host door closings, and weaker margin performance. The rating agency also added the downgrade reflects the modest erosion in liquidity due to increased borrowings under the Company's credit facility to finance the termination of its leased gold consignment program.

Intellectual Property: The Company operates 977 stores under the Finlay trade name across 15 host department store groups. In May 2005, the Company acquired Carlyle & Co. Jewelers and its subsidiaries, which operates 32 specialty jewelry stores located primarily in the southeastern United States under the Carlyle & Co., J.E. Caldwell & Co. and Park Promenade trade names. [SEC Filing 10-K 04-26-06]

Description: The Company retails fine jewelry in the U.S.

Officers: Arthur E. Reiner (Chair & CEO); Joseph M. Melvin (Pres. & COO); Leslie A. Philip (EVP & Chief Merchandising Officer); Joyce Manning Magrini (EVP-Admin.); Edward J. Stein (SVP & Dir. of Stores); Bruce E. Zurlnick (SVP, CFO, & Treas.); James Giantomenico (SVP & CIO); Bonni G. Davis (VP, Sec., & Gen. Counsel); Joan Durkin (VP & Controller); David B. Cornstein (Dir.); Rohit M. Desai (Dir.); Michael Goldstein (Dir.); Richard E. Kroon (Dir.); Ellen R. Levine (Dir.); Norman S. Matthews (Dir.); Thomas M. Murnane (Dir.)

Auditor: Deloitte & Touche LLP

Securities: 1,000 common shares outstanding as of December 1, 2006 are owned by Finlay Enterprises, Inc.
8-3/8% senior notes due June 1, 2012; senior secured revolving credit facility due January 2008.

Return to top

Prospector Profile 07.0439

GeNOsys, Inc.
280 West Riverpark Drive
Provo, UT 84604
(801) 623-4751

NAICS		541710
Employees		5
Revenue	(mil)	$0.00
Income	(mil)	($1.18)
Assets	(mil)	$1.17
Liability	(mil)	$0.06

(for the year ended 11/30/2006)

Category: Audit Concerns

Event: Mantyla McReynolds, LLC raised substantial doubt on GeNOsys, Inc.'s ability to continue as a going concern due to its recurring losses from operations since inception.

Intellectual Property: The Company has a patent application pending in Canada and the US for its nitric oxide gas generator and a design registration in Canada and the US for its medical gas generator. Management intends to continue filing patent applications or other applications that may protect proprietary compound formulation of tablets that will be utilized to produce nitric oxide gas in generators. Following further development of the generator and formulation of the compound, the Company anticipates filing patent applications in the United States, Canada and other foreign countries. [SEC Filing 10-KSB 03-15-07]

Description: The Company is engaged in medical research and development. It seeks to produce nitric oxide gas generator, medical gas generator, and compound formulation for use in generators producing nitric oxide gas for medical and non medical uses.

Officers: John W. R. Miller (Pres. & Dir.); Christie M. Woodruff Jones (Sec., Treas. & Dir.); Clark M. Mower (Dir.)

Auditor: Mantyla McReynolds, LLC

Securities: Common Stock-Symbol GNYS.OB; OTC BB;
45,668,031 common shares outstanding as of February 22, 2007.

Return to top

Prospector Profile 07.0440

Hexion Specialty Chemicals, Inc.
180 East Broad St.
Columbus, OH 43215
(614) 225-4000

NAICS		325211
Employees		6,900
Revenue	(mil)	$4,470.00
Income	(mil)	($87.00)
Assets	(mil)	$3,209.00
Liability	(mil)	$4,133.00

(for the year ended)

Category: Loss/Deficit

Event: Hexion Specialty Chemicals, Inc. reported a net loss of $55 million for the quarter ended December 31, 2006, higher than the $14 million net loss during the same period a year earlier. Revenues grew 14.5 percent to $1.31 billion for the fourth quarter, from $1.14 billion a year ago. For fiscal year 2006, the Company lost $109 million, despite a 17.2 percent gain in revenue to $5.2 billion. In 2005, it lost $87 million on revenue of $4.44 billion. The Company has an accumulated deficit of $1.183 billion and stockholder's deficit of $1.414 billion as of December 31, 2006.

Intellectual Property: The Company owns, licenses or has rights to over 1,700 patents, over 2,300 trademarks, and various patent and trademark applications and technology licenses around the world. A majority of its patents relate to developing new products and processes for manufacturing and will expire between 2007 and 2027. The Company renews the trademarks on a regular basis. While it views the patents and trademarks to be valuable, the Company does not believe that the loss or expiration of any single patent or trademark would have a material adverse effect on its results of operations, financial position or the continuation of its business. [SEC Filing 10-K 03-22-07]

Description: The Company, formerly Borden Chemical, manufactures and distributes forest product and industrial resins, formaldehyde, oilfield products and other specialty and industrial chemicals worldwide.

Officers: Craig O. Morrison (Chair, Pres. & CEO); Marvin O. Schlanger (Vice Chair); William H. Carter (EVP, CFO & Dir.); Joshua J. Harris (Dir.); Scott M. Kleinman (Dir.); Robert V. Seminara (Dir.); Jordan C. Zaken (Dir.)

Auditor: Deloitte & Touche LLP

Securities: 82,556,847 common shares outstanding as of March 1, 2007.

Notes: There is no established public trading market for the Company's common stock.

Return to top

Prospector Profile 07.0441

InSite Vision, Inc.

965 Atlantic Avenue
Alameda, CA 94501
(510) 865-8800

NAICS		325412
Employees		44
Revenue	(mil)	$0.00
Income	(mil)	($16.61)
Assets	(mil)	$2.44
Liability	(mil)	$8.74

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Burr Pilger & Mayer LLP raised substantial doubt on InSite Vision, Inc.'s ability to continue as a going concern due to its recurring losses from operations.

Intellectual Property: The Company files patent applications seeking to protect technology, inventions and improvements to inventions that are important to its business. It also relies upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain competitive position. The DuraSite drug delivery products are made under patents and applications, including two U.S. patents owned by Columbia and exclusively licensed to the Company in the field of human ophthalmic applications. In addition, the Company has filed a number of patent applications in the United States relating to its DuraSite technology with delivery tips and drug compounds. Of these applications, 7 U.S. patents have been issued. Of the patent applications licensed from the UC Regents, 12 U.S. patents have been issued. The Company has 4 U.S. patents on its retinal drug delivery device that has been issued. Three U.S. patents have been issued relating to antibiotic programs with three applications pending. In addition, foreign counterparts of its patents as well as those licensed from others have been filed in many countries. [SEC Filing 10-K 03-15-07]

Description: The Company focuses on the development and commercialization of ophthalmic pharmaceutical products in the United States.

Officers: S. Kumar Chandrasekaran, Ph.D. (Chair, Pres., CEO & CFO); Lyle M. Bowman, Ph.D. (VP-Ops.); Ronald H. Carlson (VP); David F. Heniges (VP); Sandra C. Heine (VP-Fin.)

Auditor: Burr Pilger & Mayer LLP

Securities: Common Stock-Symbol ISV; AMEX;
93,472,187 common shares outstanding as of March 15, 2007.

Return to top

Prospector Profile 07.0442

Iron Age Corporation

200 Friberg Parkway Suite 2000
Westborough, MA 01581
(412) 787-4100

NAICS 451110

Revenue	(mil)	$100.45
Income	(mil)	($81.05)
Assets	(mil)	$77.75
Liability	(mil)	$130.00

(for the year ended 1/25/2003)

Category: Section 363 Sales

Event: Iron Age Corp. will liquidate its assets in a going-out-of-business sale managed by Great American Group LLC, Bill Rochelle of Bloomberg reports. Great American will receive a 3% commission once sales reach 24.5% of retail value and will also receive a bonus if sales reach 50% of retail. The U.S. Bankruptcy Court for the District of Massachusetts had approved the Debtor's request to sell its assets on March 21, 2007.

Intellectual Property: The Company owns the Iron Age®, Knapp® and Grabber® trademarks. [SEC Filing 10-K 05-13-03]

Description: The Company sells its own shoe and footwear brands, Iron Age and Grabber, as well as those of other manufacturers through its Web site and other retailers. The Company is a wholly-owned subsidiary of Iron Age Holdings Corp. The Company filed for Chapter 11 protection on January 22, 2007, with the U.S. Bankruptcy Court in the District of Massachusetts (Worcester), case numbers 07-40217 and 07-40219, before Judge Joel B. Rosenthal.

Officers: David Eckert (Pres. & CEO); Paul Russo (CFO); Jeff Hoburg (VP)

Auditor: Ernst & Young LLP

Attorneys: Christopher J. Panos, Esq. and Kathleen Rahbany, Esq. of Craig and Macauley PC; Boston, MA; (617) 367-9500

Securities: 1,000 common shares outstanding as of May 12, 2003.

Notes: The Company has ceased filing its financial report with the U.S. Securities and Exchange Commission since 2004.

Return to top

Prospector Profile 07.0443

Liquidmetal Technologies, Inc.

25800 Commercentre Drive, Suite 100
Lake Forest, CA 92630
(949) 206-8000

NAICS		331513
Employees		690
Revenue	(mil)	$27.67
Income	(mil)	($14.52)
Assets	(mil)	$22.24
Liability	(mil)	$32.61

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Choi, Kim & Park LLP expressed substantial doubt on Liquidmetal Technologies Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the fiscal years ended December 31, 2006 and 2005. The auditing firm pointed to the Company's significant operating losses and working capital deficit.

Intellectual Property: The Company's intellectual property consists of patents, trade secrets, know-how, and trademarks. Protection of intellectual property is a strategic priority for its business, and the Company intends to vigorously protect patents and other intellectual property. The Company's intellectual property portfolio includes 32 owned or licensed U.S. patents and numerous patent applications relating to the composition, processing, and application of alloys, as well as various foreign counterpart patents and patent applications. The initial bulk amorphous alloy technology was developed by researchers at the California Institute of Technology and the Company has purchased patent rights for the exclusive right to commercialize amorphous alloy and other amorphous alloy technology through a license agreement. [SEC Filing 10-K 03-16-07]

Description: The Company develops, manufactures, and sells products made from bulk amorphous alloys through its Liquidmetal Alloy Industrial Coatings and Bulk Liquidmetal Alloys business segments.

Officers: John Kang (Chair); Larry E. Buffington (Pres. & CEO); Young J. Ham (CFO & Sec.); Dean G. Tanella (Dir.); William Johnson (Dir.); Robert Biehl (Dir.); Patrick P. Caruana (Dir.); CK Cho (Dir.)

Auditor: Choi, Kim & Park LLP

Securities: Common Stock Symbol LQMT.OB; OTCBB;
44,311,768 common shares outstanding as of February 1, 2007.
6% senior secured notes due July 2007; 7% senior secured convertible notes due August 2007; 8% convertible subordinated notes due January 2010.

Return to top

Prospector Profile 07.0444

Magna Entertainment Corporation

337 Magna Drive
Aurora, Ontario L4G 7K1
Canada
(905) 726-2462

NAICS		711212
Employees		5,300
Revenue	(mil)	$702.14
Income	(mil)	($87.35)
Assets	(mil)	$1,246.89
Liability	(mil)	$846.27

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP raised substantial doubt about Magna Entertainment Corp.'s ability to continue as a going concern after auditing the Company's financial statements for the fiscal years ended December 31, 2006, and 2005. The accountants pointed to the Company's recurring operating losses and working capital deficiency.

Intellectual Property: The Company's intellectual property ranges from ownership of racing content and the pari-mutuel racing event that is determined by the race outcome, to the techniques and technology used to process wagers placed on the pari-mutuel racing event. In recent years, the Company has focused on the creation of alternative pari-mutuel wagering solutions, new wager types that use existing pari-mutuel wagering solutions and exploration in the development of wagers for non-traditional pari-mutuel wagering events. Acquisition of intellectual property has and will continue to include in-house research and development and the purchasing of intellectual property developed outside of the company. Its intellectual property management includes the filing of patents, regular review of patents filed and awarded, review of the competitive landscape and review of the legislative landscape nationally and internationally. [SEC Filing 10-K 03-14-07]

Description: The Company owns and operates horse racetracks and supplies racing content to the inter-track, off-track, and account wagering markets in North America.

Officers: Frank Stronach (Chair); Michael A. Neuman (CEO & Dir.); Blake Tohana (EVP & CFO); Joe De Francis (EVP); Jerry D. Campbell (Dir.); Joseph De Francis (Dir.); Louis E. Lataif (Dir.); William J. Menear (Dir.); Dennis Mills (Dir.); Charlie J. Williams (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol MECA; NasdaqGM;
107,567,471 common shares outstanding as of March 8, 2007.
8.55% convertible subordinated notes due June 15, 2010; 7.25% convertible subordinated notes due December 15, 2009.

Return to top

Prospector Profile 07.0445

MediStem Laboratories, Inc.
2027 East Cedar Street, Suite 102
Tempe, AZ 85281
(954) 727-3662

NAICS		541710
Employees		5
Revenue	(mil)	$0.32
Income	(mil)	($3.79)
Assets	(mil)	$1.78
Liability	(mil)	$0.26

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Beckstead & Watts, LLP expressed substantial doubt on MediStem Laboratories, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has had limited operations and has not commenced planned principal operations.

Intellectual Property: The Company's current intellectual property portfolio consists of 8 patents pending with over 2,000 cumulative claims. The Company's trade secrets and know-how covers methods of generating and using adult stem cells in a variety of clinical settings. The patents pending range from unique methods of minimizing the rejection rate of injected stem cells, to methods for expanding stem cells, to treatments of various disorders utilizing stem cells. The Company's trade secrets and know-how cover ways of generating and practically using adult stem cells in a variety of clinical settings. Its licensing program allows the utilization of such modern-day stem cell technology to be applied in clinics that are approved by regional governments to practice stem cell therapy. Through licensing, the Company can generate substantial revenues while simultaneously gaining access to invaluable clinical data that will strengthen its ability to generate meaningful intellectual property. [SEC Filing 10-KSB 03-15-7]

Description: The Company focuses on the clinical application of adult stem cells, as well as the administration of adult stem cells.

Officers: Neil H. Riordan (Chair, Pres. & CEO); Roger M. Nocera (EVP, Chief Medical Officer & Dir.); Chris McGuinn (VP & COO); Steven M. Rivers (CFO); John Peterson (Dir.)

Auditor: Beckstead & Watts, LLP

Securities: Common Stock-Symbol MDSM.OB; OTC BB;
131,405,693 common shares outstanding as of February 28, 2006.

Return to top

Prospector Profile 07.0446

Miracor Diagnostics, Inc.

9191 Towne Centre Drive, Suite 400
San Diego, CA 92122
(858) 455-7127

NAICS		621512
Employees		128
Revenue	(mil)	$19.51
Income	(mil)	$0.66
Assets	(mil)	$21.43
Liability	(mil)	$18.49

(for the year ended 12/31/2005)

Category: Restructuring

Event: Miracor Diagnostics, Inc. initiated a restructuring plan on its equipment financing because cash flow from operations does not support the cash flow required to service such equipment financing. The recent implementation of the Deficit Reduction Act adversely affected the Company's revenue. Because of this development, the Company is discontinuing its principal and interest payments to the secured equipment lenders as well as certain payment to unsecured creditors and preferred shareholders. The Company may seek Chapter 11 protection in an effort to reorganize its debts in the events its restructuring initiative is unsuccessful.

Intellectual Property: The Company is engaged in the development of the Fluid Alarm System, which monitored the integrity of infection control barriers worn during medical procedures, and the Cell Recovery System, which was a cell "brushing" and retrieval system that used an automated biopsy brush for the collection of specimen cells for diagnostic purposes. The Company has the patent licensing rights through the life of the patents which expire from 2008 to 2010. [SEC Filing 10-KSB 03-30-06]

Description: The Company provides medical diagnostic imaging services, which include primarily magnetic resonance imaging and computed tomography services, in the U.S.

Officers: Ross Seibert (Pres., CEO, & CFO); Leslie Weber (COO & Chief Mktg. Officer); Howard Salmon (Dir.); Stephen A. McConnell (Dir.); David Schack (Dir.)

Auditor: Tschopp, Whitcomb, & Orr PA

Securities: Common Stock Symbol MRDG.OB; OTCBB;
21,091,604 common shares outstanding as of October 31, 2006.

Return to top

Prospector Profile 07.0447

MultiCell Technologies, Inc.
701 George Washington Highway
Lincoln, RI 02865
(401) 333-0610

NAICS		541710
Employees		8
Revenue	(mil)	$0.68
Income	(mil)	($5.42)
Assets	(mil)	$1.51
Liability	(mil)	$2.89

(for the year ended 11/30/2006)

Category: Audit Concerns

Event: J. H. Cohn LLP expressed substantial doubt about MultiCell Technologies, Inc.'s ability to continue as a going concern because the Company has sustained substantial losses and has an accumulated deficit at November 30, 2006.

Intellectual Property: On September 7, 2005, the Company acquired intellectual property from Alliance Pharmaceutical Corp. and Astral, Inc. including 10 United States and 20 foreign issued and pending patents and patent applications related to chimeric antibody technology, treatment of Type 1 diabetes, T-cell tolerance, toll-like receptor technology, dendritic cells, dsRNA technology and immunosuppression. In December 2003, the Company acquired the exclusive worldwide rights to US Patent # 6129911 for Liver Stem Cells from Rhode Island Hospital. In April, 2005, the Company was granted US Patent # 6872389 for the liver stem cell invention of SVP and Chief Scientific Officer Dr. Ron Faris. This patent contains 24 claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio. The Company has an exclusive, long-term license agreement with Rhode Island Hospital for use 6 patents owned by the hospital related to liver cell lines and Liver Assist Devices. On November 3, 2003, its Xenogenics Corp. subsidiary was notified by the US Patent and Trademark Office that it was granted patent 6,858,146 for an "Artificial Liver Apparatus And Method" and the Sybiol® Synthetic Bio-Liver Device. The Sybiol® trademark is registered in the United States Patent and Trademark Office. [SEC Filing 10-K 03-15-07]

Description: MultiCell Technologies, Inc. develops and commercializes therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms.

Officers: W. Gerald Newmin (Chair, CFO, Sec. & Treas.); Stephen Chang (Pres., CEO & Dir.); Edward Sigmond (Dir.); Thomas A. Page (Dir.); Anthony Altig (Dir.)

Auditor: J. H. Cohn LLP

Securities: Common Stock-Symbol MCET.OB; OTC BB;
40,843,896 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0448

NBO Systems, Inc.
3676 West California Avenue, Building D
Salt Lake City, UT 84104
(801) 746-8000

NAICS		323110
Employees		41
Revenue	(mil)	$11.31
Income	(mil)	($5.51)
Assets	(mil)	$18.26
Liability	(mil)	$31.46

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Tanner LC raised substantial doubt about NBO Systems, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the fiscal years ended December 31, 2006, and 2005. The auditor pointed to the Company's working capital deficiency and accumulated deficit.

Intellectual Property: The Company relies on a combination of trademark, copyright, and trade secret law and contractual restrictions with customers, suppliers and consultants to protect intellectual property rights. The Company has filed two federal applications with the US Patent and Trademark Office for the trademarks and service marks relating to the marketing and sale of products and services. It has licensed, and may license in the future, elements of trademarks, trade dress and similar proprietary rights to third parties. [SEC Filing 10-K 03-26-07]

Description: The Company is an innovator of flexible and powerful prepaid card technology. It partners with organizations to consistently develop and implement prepaid card programs.

Officers: Keith A. Guevara (Chair, Pres., & CEO); John J. Arego (VP-Technology & Information Systems); Chris McGee (VP-Business Dev't.); Christopher Foley (CFO & Dir.); D. Kent Jasperson (Chief Acctg. Officer & Controller); Andrew Boyd-Jones (Dir.)

Auditor: Tanner LC

Securities: 18,669,916 common shares outstanding as of March 26, 2007.

Return to top

Prospector Profile 07.0449

Neah Power Systems, Inc.

22122 20th Avenue SE, Suite 161
Bothell, WA 98021
(425) 424-3324

NAICS		334413
Employees		13
Revenue	(mil)	$0.13
Income	(mil)	($15.17)
Assets	(mil)	$4.62
Liability	(mil)	$8.60

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Peterson Sullivan PLLC expressed substantial doubt about the ability of Neah Power Systems Inc. to continue as a going concern citing the company's recurring losses from operations after auditing the company's financial results as of Dec. 31, 2006 and 2005.

Intellectual Property: The Company relies upon its trade secret protection program and non-disclosure safeguards to protect its proprietary computer technologies, software applications and systems know-how. In the ordinary course of business, the Company enters into license agreements and contracts which specify terms and conditions prohibiting unauthorized reproduction or usage of the Company's proprietary technologies and software applications. In addition, the Company generally enters into confidentiality agreements with its employees, clients, potential clients and suppliers with access to sensitive information and limits the access to and distribution of its software documentation and other proprietary information. The Company believes that there is rapid technological change in its business and, as a result, legal protections generally afforded through patent protection for its products are less significant than the knowledge, experience and know-how of its employees, the frequency of product enhancements and the timeliness and quality of customer support in the usage of such products. [SEC Filing 10-KSB 03-19-07]

Description: The Company focuses on developing miniature fuel cells that are used as power sources in laptop computers, cell phones, personal digital assistants, and other portable electronic devices.

Officers: J. Jeremy Barbera (Chair & CEO); John T. Gerlach (Dir.); Seymour Jones (Dir.); Joseph Peters (Dir.); David Stoller (Dir.)

Auditor: Peterson Sullivan PLLC

Securities: Common Stock-Symbol MSGI.PK; PNK;
103,162,431 common shares outstanding as of March 14, 2007.

Return to top

Prospector Profile 07.0450

Oragenics, Inc.
13700 Progess Boulevard
Alachua, FL 32615
(386) 418-4018

NAICS		541710
Employees		10
Revenue	(mil)	$0.07
Income	(mil)	($2.94)
Assets	(mil)	$1.61
Liability	(mil)	$0.33

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Kirkland Russ Murphy & Tapp, PA raised substantial doubt about Oragenics, Inc.'s ability to continue as a going concern. The auditor noted that the Company has incurred recurring operating losses, negative operating cash flows and has an accumulated deficit.

Intellectual Property: The Company has exclusively licensed the intellectual property for its replacement therapy from the University of Florida Research Foundation, Inc. The agreement provides the Company with an exclusive worldwide license to make, use and sell products and processes covered by Patent No. 5,607,672. The patent covers the genetically altered strain of Streptococcus mutans which does not produce lactic acid, a pharmaceutical composition for administering the genetically altered strain and the method of preventing tooth decay by administering the strain. [SEC Filing 10-KSB 03-23-07]

Description: The Company has a number of products in discovery with a concentration in two main therapeutic areas: infectious disease and oncology.

Officers: David J. Gury (Chair); Robert T. Zahradnik (Pres. & CEO); Paul A. Hassie (CFO, Sec. & Treas.); Brian Anderson (Dir.); George T. Hawes (Dir.); Jeffrey D. Hillman (Dir.)

Auditor: Kirkland Russ Murphy & Tapp, PA

Securities: Common Stock-Symbol ONI; AMEX;
19,646,117 common shares outstanding as of March 6, 2006.

Return to top

Prospector Profile 07.0451

Oscient Pharmaceuticals Corporation

1000 Winter Street, Suite 2200
Waltham, MA 02451
(781) 398-2300

NAICS		541710
Employees		336
Revenue	(mil)	$46.15
Income	(mil)	($78.48)
Assets	(mil)	$279.41
Liability	(mil)	$281.40

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Oscient Pharmaceuticals Corporation reported a net loss of $78.477 million for the year ended December 31, 2006, lower than the net loss reported in previous years of $88.593 million in 2005 and $93.271 million in 2004. The Company reported sales of $46.152 million in 2006, higher than the reported sales of $23.609 million in 2005 and $6.613 million in 2004. As a result of its recurring losses, the Company has $415.905 million in accumulated deficit and $1.996 million in stockholder's deficit as of December 31, 2006.

Intellectual Property: The Company currently owns or licenses 75 issued U.S. patents, 87 pending U.S. patent applications, 148 issued foreign patents and 201 pending foreign patent applications. These patents and patent applications primarily relate to the chemical composition, use, and method of manufacturing FACTIVE; pharmaceutical compositions, methods of their use and treatment, and methods of manufacturing ANTARA; metalloenzyme inhibitors, their uses and their targets; anti-infective compounds and their uses; and the field of human and pathogen genetics. The Company also has the exclusive right to use FACTIVE trademarks, trade names, domain names and logos in conjunction with the use or sale of the product in the territories covered by the license. The Company acquired exclusive rights to ANTARA trademarks, trade names, domain names and logos. [SEC Filing 10-K 03-15-07]

Description: The Company engages in the clinical development and commercialization of therapeutics to serve medical needs in the United States.

Officers: David K. Stone (Chair); Steven M. Rauscher (Pres., CEO & Dir.); Philippe M. Maitre (SVP & CFO); Dominick C. Colangelo (EVP); Gregory B. Brown, M.D. (Dir.); Walter Flamenbaum, M.D. (Dir.); Robert J. Hennessey (Dir.); William R. Mattson (Dir.); Gary Patou, M.D. (Dir.); Williams S. Reardon (Dir.); Norbert G. Riedel, Ph.D. (Dir.); John E. Voris (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol OSCI; NasdaqGM;
13,642,361 common shares outstanding as of March 6, 2007.

Return to top

Prospector Profile 07.0452

Pathogenics, Inc.

99 Derby Street, Suite 200
Hingham, MA 02043
(781) 556-1090

NAICS		541710
Employees		1
Revenue	(mil)	$0.15
Income	(mil)	($0.26)
Assets	(mil)	$0.23
Liability	(mil)	$0.64

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Malone & Bailey, PC raised substantial doubt about Pathogenics, Inc.'s ability to continue as a going concern due to its significant losses since inception. A significant amount of additional capital will be necessary to advance the development of the Company's products to the point at which they may become commercially viable.

Intellectual Property: The Company holds rights under a license agreement entered into March 29, 2006 with Dr. Waldemar Gottardi and Dr. Markus Nagl, to worldwide exclusive license patent rights in connection with patents relating to N-Chlorotaurine and any technology relating to those patent rights or improvements. The Company has one issued European patent and currently pending four German patent applications, two Patent Cooperation Treaty applications, and one US patent application pending which cover the use of N-chlorotaurine for the treatment of chronic sinus infections, for treating oozing tissue deficiencies and its use as a fungicidal agent and against protozoa, as well as an improved therapeutic formulation for the treatment of conjunctivitis. On April 13, 2006, the Company entered into a patent license agreement with Acuity Pharmaceuticals, Inc., under which Acuity gains exclusive worldwide development and commercialization rights to N-Chlorotaurine. [SEC Filing 10-KSB 03-15-07]

Description: The Company acquires and develops new therapeutic drugs that have large sales potential and target unmet medical needs.

Officers: Frederic P. Zotos (Pres., CEO, Sec., Treas. & Dir.); Michael Ferrari (VP & Dir.)

Auditor: Malone & Bailey, PC

Securities: Common Stock-Symbol PTGN.PK; PNK;
49,567,615 common shares outstanding as of March 12, 2007.

Return to top

Prospector Profile 07.0453

Pegasus Solutions, Inc.
8350 N. Central Expressway, Suite 1900
Dallas, TX 75206
(214) 234-4000

NAICS		561599
Employees		1,049
Revenue	(mil)	$175.48
Income	(mil)	($7.66)
Assets	(mil)	$315.12
Liability	(mil)	$140.99

(for the year ended 12/31/2005)

Category: Low Rating

Event: Moody's Investors Service assigned its Caa1, LGD5, 73% rating to Pegasus Solutions, Inc.'s $120 million 8-year senior unsecured notes. The rating outlook is stable. The proceeds from the $120 million note offering and $60 million term loan facility will be used to repay the existing senior secured credit facility, pay a $60 million dividend to shareholders and pay related transaction expenses.

Intellectual Property: The Company is continually developing new technology and enhancing existing proprietary technology. Currently, one US patent has been issued and a second US patent has been allowed and is expected to be issued in the second half of 2006. In addition, the Company has filed a total of six patent applications in Australia, Canada and the European Union. One patent application in China has been allowed but has not yet issued, and the remainder are in various stages of the application process. The Company primarily relies on a combination of trademark, copyright, trade secrets, confidentiality procedures and contractual provisions to protect technology and other intellectual property rights. [SEC Filing 10-K 03-16-06]

Description: The Company provides technology and services to hotels and travel distributors with its central reservation systems, electronic distribution services, commission processing and payment services, and marketing representation services, including the consumer Web site hotelbook.com™.

Officers: John F. Davis, III (Chair & CEO); Michael H. Kistner (Pres. & COO); Mark S. Dubrow (Pres.); William C. Hammett, Jr. (CFO & Dir.); Christopher Klimko (SVP & Gen. Counsel); David Chestler (SVP-Dev't.); Michael A. Barnett (Dir.); Robert B. Collier (Dir.); Thomas F. O'Toole (Dir.); Pamela H. Patsley (Dir.); Jeffrey A. Rich (Dir.); Bruce W. Wolff (Dir.)

Auditor: PricewaterhouseCoopers LLC

Securities: 20,804,229 common shares outstanding as of March 9, 2006.
3.875% convertible senior notes due 2023

Return to top

Prospector Profile 07.0454

Progressive Gaming International Corp.

920 Pilot Road
Las Vegas, NV 89119
(702) 896-3890

NAICS		713290
Employees		308
Revenue	(mil)	$69.51
Income	(mil)	$36.62
Assets	(mil)	$186.19
Liability	(mil)	$102.26

(for the year ended 12/31/2006)

Category: Miscellaneous

Event: Progressive Gaming International Corp. disclosed in its SEC filing that they will have no choice but to file for Chapter 11 protection if its appeal on a $43.7 million lawsuit judgment fails. On December 27, 2002, Derek Webb and related plaintiffs filed a case against the Company in the U.S. District Court for the Southern District of Mississippi alleging state law interference with business relations claims and federal antitrust violations. The plaintiffs contended that the Company illegally restrained trade and attempted to monopolize the proprietary table game market. On February 21, 2007, the Court's judgment favored the plaintiffs for costs. The Company said it filed post-trial claims for relief and intends to initiate the appeals process.

Intellectual Property: The Company believes that intellectual property rights, patents, trademarks and copyrights are significant assets. In particular, it owns or has license rights to over 40 patents in the area of RFID technology and related table games system management. In addition, the Company also relies on strategic partnerships to obtain access to intellectual property. The Company trademarks include: Casinolink® Enterprise Edition™, Casinolink® Patron Suite™, Casinolink® Intelligence Suite™, Casinolink® Gaming Suite™, Casinolink® Jackpot Module™, World Series of Poker® Texas Hold 'Em Bonus®, Texas Hold 'Em Bonus®, Caribbean Stud®, Two-Card Joker Poker™, Progressive Blackjack®, Progressive Baccarat™, Graveyard Bash™, Office Daze™, Rapid Bet Live™. [SEC Filing 10-K 03-23-07]

Description: The Company supplies integrated casino and jackpot management solutions for the gaming industry worldwide.

Officers: Peter G. Boynton (Chair); Russell H. McMeekin (CEO); Heather A. Rollo (EVP, CFO, & Treas.); Paul A. Harvey (Dir.); Terrance W. Oliver (Dir.); Rick L. Smith (Dir.); Douglas M. Todoroff (Dir.); Robert J. Parente (Dir.); Thomas M. Galanty (Dir.); Robert B. Zeims (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol PGIC; NasdaqGM;
34,824,254 common shares outstanding as of March 12, 2007.

Return to top

Prospector Profile 07.0455

Protection One, Inc.

1035 North 3rd Street, Suite 101
Lawrence, KS 66044
(785) 856-5500

NAICS		561621
Employees		2,500
Revenue	(mil)	$270.55
Income	(mil)	($17.41)
Assets	(mil)	$443.95
Liability	(mil)	$523.90

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Protection One, Inc. posted a net loss of $17,405,000 on revenues of $270,552,000 for the year ended December 31, 2006, as compared with a net loss of $26,993,000 on revenues of $263,024,000 for the same period in 2005. As of December 31, 2006, the Company's balance sheet showed strained liquidity with $64,647,000 in total current assets and $69,637,000 in total current liabilities. The Company also reported $79,943,000 in stockholders' deficit and $169,352,000 in accumulated deficit.

Intellectual Property: The Company owns trademarks related to the name and logo for Protection One and Network Multifamily Security as well as a variety of trade and service marks related to individual services. [SEC Filing 10-K 03-16-07]

Description: The Company provides security alarm monitoring services to single-family residential, commercial, multifamily, and wholesale customers in the U.S.

Officers: Richard Ginsburg (Pres., CEO, & Dir.); Darius Nevin (EVP, CFO, & Dir.); Peter Pefanis (EVP-Field Operations); J. Eric Griffin (VP, Sec., & Gen. Counsel); Joseph Sanchez (VP-Customer Operations)

Auditor: Deloitte & Touche LLP

Securities: Common Stock Symbol PONN.OB; OTCBB;
18,239,953 common shares outstanding as of March 10, 2007.
7.86% senior credit facility due March 31, 2012;
8.125% senior subordinated notes due January 2009.

Return to top

Prospector Profile 07.0456

Revlon, Inc.
237 Park Avenue
New York, NY 10017
(212) 527-4000

NAICS		325000
Employees		6,000
Revenue	(mil)	$1,331.40
Income	(mil)	($251.30)
Assets	(mil)	$931.90
Liability	(mil)	$2,161.70

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Revlon, Inc. posted a net loss of $251,300,000 on revenues of $1,331,400,000 for the fiscal year ended December 31, 2006, as compared with a net loss of $83,700,000 on revenues of $1,332,300,000 for the same period in 2005. As of December 31, 2006, the Company's balance sheet showed $1,229,800,000 in stockholders' deficit and $1,993,200,000 in accumulated deficit.

Intellectual Property: The Company's major trademarks are registered in the U.S. and over 100 other countries. Significant trademarks include Revlon, ColorStay, Revlon Age Defying with Botafirm, Super Lustrous, Almay, Mitchum, Flex, Charlie, Jean Naté, Moon Drops, Colorsilk, Frost & Glow, Revlon Custom Effects, Expert Effect, Skinlights, Eterna 27, Illuminance and, outside the U.S., Bozzano, Cutex, Gatineau and Ultima II. The Company utilizes certain proprietary, patent pending or patented technologies in the formulation or manufacture of a number of the Company's products, including ColorStay cosmetics, classic Revlon nail enamel; Revlon Age Defying with Botafirm foundation and cosmetics; Revlon Fabulash mascara; Revlon Colorist haircolor; Almay Clear Complexion liquid foundation makeup; Almay Line Smoothing liquid foundation makeup; Almay One Coat cosmetics; Almay SmartShade makeup; Almay Nearly Naked makeup; and Mitchum Cool Dry anti-perspirant. The Company also protects its packaging and component concepts through design patents. [SEC Filing 10-K 03-13-07]

Description: The Company manufactures, markets and sells an extensive array of cosmetics, skin care, and other personal care products, through its direct wholly owned operating subsidiary, Revlon Consumer Products Corp. and its subsidiaries.

Officers: Ronald O. Perelman (Chair); David L. Kennedy (Pres, CEO & Dir.); Alan T. Ennis (EVP, CFO, Chief Acctg. Officer, & Controller); Robert K. Kretzman (EVP-HR, Chief Legal Officer & Gen. Counsel); Neil Scancarella (EVP & Chief Scientific Officer)

Auditor: KPMG LLP

Securities: Common Stock Symbol REV; NYSE;
412,700,845 common shares outstanding as of December 31, 2006.
9-1/2% senior notes due 2011; 8-5/8% senior subordinated notes due 2008.

Return to top

Prospector Profile 07.0457

Sparta Commercial Services, Inc.
462 Seventh Avenue, 20th Floor
New York, NY 10018
(212) 239-2666

NAICS		522220
Employees		15
Revenue	(mil)	$0.17
Income	(mil)	($5.96)
Assets	(mil)	$3.06
Liability	(mil)	$2.52

(for the year ended 4/30/2006)

Category: Loss/Deficit

Event: Sparta Commercial Services, Inc. disclosed that its balance sheet at Jan. 31, 2007, showed total stockholders' deficit of $644,623, resulting from total assets of $4,232,370 and total liabilities of $4,876,993. The Company also listed an accumulated deficit of $17,230,171, as compared with an accumulated deficit of $14,150,429 as of April 30, 2006. The Company's balance sheet also showed strained liquidity with total current assets of $696,413 available to pay total current liabilities of $2,684,270. For the quarter ended Jan. 31, 2007, the Company reported a net loss of $932,387 on revenues of $214,642, as compared with a net loss of $3,658,551 on revenues of $43,008 for the quarter ended Jan. 31, 2006. For the nine months ended Jan. 31, 2007, the Company had a net loss of $2,989,931 on revenues of $625,839, as compared with a net loss of $6,734,000 on revenues of $90,629 for the same period a year earlier.

Intellectual Property: The Company's retail installment sales contract and leasing programs are delivered through a proprietary, web-based, credit application processing system. This system is named iPLUS and is structured as an Application Service Provider and has the capability of providing the dealer with conditional approvals seven days a week, 24 hours a day. This system also provides the powersports dealer with system capabilities comparable to those of new car franchises. [SEC Filing 10-KSB 08-22-06]

Description: The Company engages primarily in the origination of lease and retail installment sales contracts of new and used motorcycles, scooters, and all-terrain vehicles in the United States.

Officers: Anthony L. Havens (Chair, Pres., CEO & CFO); Richard P. Trotter (COO); Sandra L. Ahman (VP, Sec. & Dir.); Kristian Srb (Dir.); Jeffrey Bean (Dir.)

Auditor: Russell Bedford Stefanou Mirchandani LLP

Securities: Common Stock-Symbol SRCO.OB; OTC BB;
123,216,157 common shares outstanding as of March 17, 2007.

Return to top

Prospector Profile 07.0458

Steakhouse Partners, Inc.

10200 Willow Creek Road
San Diego, CA 92131
(858) 689-2333

NAICS		722210
Employees		1,300
Revenue	(mil)	$50.17
Income	(mil)	($1.77)
Assets	(mil)	$29.41
Liability	(mil)	$23.55

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Mayer Hoffman McCann PC raised substantial doubt about Steakhouse Partners, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the fiscal years ended December 31, 2006, and 2005. The auditor pointed to the Company's working capital deficiency and accumulated deficit.

Intellectual Property: The Company has registered various service marks, including Hungry Hunter, Hunter Steakhouse, Mountain Jack's and Carvers and their related designs with the United States Patent and Trademark Office. All of its trademarks and service marks have stated expiration dates ranging from 2008 to 2012. However, they are renewable for an unlimited number of additional 10-year terms at the Company's option. [SEC Filing 10-K 03-28-07]

Description: The Company owns and operates steakhouse restaurants in the U.S. under the brand names of Hungry Hunter® , Hunter Steakhouse®, Mountain Jack's®, and Carvers®.

Officers: A. Stone Douglass (Chair, Pres., CEO, & Sec.); Susan Schulze-Claasen (EVP, Chief Admin. Officer, & Gen. Counsel); Joseph L. Wulkowicz (VP & CFO); Edgar Tod Lindner (Dir.); Thomas A. Edler (Dir.); T. Scott Avila (Dir.)

Auditor: Mayer Hoffman McCann PC

Securities: Common Stock Symbol STKP.OB; OTCBB;
6,635,680 common shares outstanding as of March 26, 2007.
9% secured note due January 1, 2008; 9% notes due January 31, 2009.

Return to top

Prospector Profile 07.0459

Sungold International Holdings Corp.
300-940 The East Mall
Toronto, Ontario M9B 6J7
Canada
(416) 620-1545

NAICS	511210	
Employees	3	
Revenue	CAD(mil)	$0.00
Income	CAD(mil)	($1.57)
Assets	CAD(mil)	$0.77
Liability	CAD(mil)	$0.66

(for the year ended 8/31/2006)

Category: Audit Concerns

Event: Mintz & Patners LLP expressed doubt about Sungold International Holdings Corp.'s ability to continue as a going concern because it has experienced significant recurring losses and negative cash flow from operations over a number of years.

Intellectual Property: In May, 2001, the Corporation acquired the right, title and interest to the internet payment system technology of SafeSpending™. It is intended to become a prepaid spending system that uses a unique and personalized PIN number, which can be used to make anonymous purchases online from merchants and individuals. The acquisition agreement includes all copyrights, trademarks, source codes and SafeSpending's intellectual property. The Company owns the online rights, title and interest in the Horsepower® proprietary, pari-mutuel, virtual, horseracing system. [SEC Filing 20-F 03-15-07]

Description: The Company engages in the development and operation of virtual horse racing software system and design of online Internet prepayment system in Canada.

Officers: Donald R. Harris (Chair); Art Cowie (Vice Chair); Dennis Hedtke (Dir.); Larry Simpson (Dir.)

Auditor: Mintz & Patners LLP

Securities: Common Stock-Symbol SGIHF.OB; OTC BB;
126,375,535 common shares outstanding as of March 15, 2007.

Return to top

Prospector Profile 07.0460

The Allied Defense Group, Inc.

8000 Towers Crescent Drive, Suite 260
Vienna, VA 22182
(703) 847-5268

NAICS		561620
Employees		694
Revenue	(mil)	$128.69
Income	(mil)	($41.10)
Assets	(mil)	$168.05
Liability	(mil)	$112.70

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: BDO Seidman LLP raised substantial doubt on Allied Defense Group, Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the fiscal years ended December 31, 2006, and 2005. The auditing firm pointed to the Company's losses from operations and default notices from debt holders.

Intellectual Property: The Company's News/Sports Microwave Rental, Inc. subsidiary holds a patent on a mechanical mast that is a key component of certain security systems it supplies to law enforcement agencies. Its Titan Dynamic Systems, Inc. subsidiary holds patents on its weapon discharge simulation system (granted in 1993), its electrostatically dischargeable primer (granted in 1999), its electric impulse cartridge (granted in 2001) and an electric gun (granted in 2002). Titan also has the TERASCAN and SEASPACE trademarks and has a patent pending on its new AXYOM antenna technology. [SEC Filing 10-K 03-23-07]

Description: The Company designs, develops, manufactures, and sells ammunition and light weapons for military use. It also provides microwave surveillance and security systems for government and private industry.

Officers: J. H. Binford Peay III (Chair); John J. Marcello (Pres. & CEO); Monte L. Pickens (EVP & COO); Robert P. Dowski (CFO); Ronald H. Griffith (Dir.); Gilbert F. Decker (Dir.); John G. Meyer, Jr. (Dir.); Charles S. Ream (Dir.); Thomas R. Hudson, Jr. (Dir.); Frederick G. Wasserman (Dir.)

Auditor: BDO Seidman LLP

Securities: Common Stock Symbol ADG; AMEX;
6,440,944 common shares outstanding as of February 28, 2007.
7.5% senior subordinated convertible notes.

Return to top

Prospector Profile 07.0461

Tweeter Home Entertainment Group, Inc.

40 Pequot Way
Canton, MA 02021
(781) 830-3000

NAICS		443112
Employees		3,200
Revenue	(mil)	$775.29
Income	(mil)	($16.48)
Assets	(mil)	$258.57
Liability	(mil)	$190.42

(for the year ended 9/30/2006)

Category: Restructuring

Event: Tweeter Home Entertainment Group, Inc. plans to consolidate and reinvest its resources to expand its popular "Consumer Electronics Playground" concept stores in an effort to substantially improve its short and long-term financial health. Tweeter's plan includes closing 49 stores, two regional facilities, and exiting certain regions of the country. The Company will close all of its stores in California, Tennessee, Alabama, New York, and most of Georgia within two to three months, resulting in layoffs of about 20% of its total work force.

Intellectual Property: The Company has registered the "Tweeter" and "Tweeter etc." service marks with the United States Patent and Trademark Office. It has also registered the "Prosolutions" trademark and the "AVi.d. Member," "Slamfest," "Wise Buys" and "Picture Perfect" service marks with the United States Patent and Trademark Office. The Company has not registered "hifi buys," "Sound Advice" and some other service marks. The Company has submitted applications for registration of some of its other service marks, which applications are currently pending. [SEC Filing 10-K 12-21-06]

Description: The Company sells audio, video, entertainment, and mobile consumer electronic products through its chain of stores under the Tweeter, hifi buys, Sound Advice, and Showcase Home Entertainment names.

Officers: Samuel Bloomberg (Chair); Joseph McGuire (Pres., CEO, & Dir.); Gregory Hunt (SVP & CFO); Robert Staples (SVP-Sales & Installation Services); Jeffrey Bloomberg (Dir.); Michael Cronin (Dir.); John Esposito (Dir.); Steven Fischman (Dir.); Karen Kaplan (Dir.); John Mahoney (Dir.); Jeffrey Stone (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock Symbol TWTR; NasdaqGM;
25,527,943 common shares outstanding as of February 1, 2007.

Return to top

Prospector Profile 07.0462

Viewpoint Corporation

498 Seventh Avenue, Suite 1810
New York, NY 10018
(212) 201-0800

NAICS		541613
Employees		91
Revenue	(mil)	$17.18
Income	(mil)	($19.72)
Assets	(mil)	$27.69
Liability	(mil)	$7.99

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PricewaterhouseCoopers LLP expressed substantial doubt about Viewpoint Corp.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the fiscal years ended December 31, 2006, 2005, and 2004. The auditing firm pointed to the Company's negative cash flow from operations, net losses since inception, and limited capital to fund future operations.

Intellectual Property: The Company's Viewpoint Toolbar technology enables consumers to search the Internet for goods, services and information. Unlike other toolbars, however, the Viewpoint Toolbar's architecture enables features such as visual representations of search results and "bookmarked" internet sites, automatic updating, generation of desktop animations, and a "Pop-Up" blocker that intercepts pop-up advertisements and holds them in a "tray" of the Viewpoint Toolbar. The Company is in the process of applying for patent protection on several of these features and processes. [SEC Filing 10-K 03-16-07]

Description: The Company operates as an Internet marketing technology company. It offers digital products, services, and consulting for Internet marketers.

Officers: Patrick Vogt (Pres., CEO & Dir.); Christopher C. Duignan (Interim CFO); Andrew J. Graf (VP & Gen. Counsel); Samuel H. Jones, Jr. (Dir.); Dennis R. Raney (Dir.); James J. Spanfeller (Dir.); Harvey D. Weatherson (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol VWPT; NasdaqGM;
67,670,000 common shares outstanding as of March 12, 2007.
5.00% promissory note due February 2011; 4.95% subordinated note payable Sept. 30, 2009.

Return to top

Prospector Profile 07.0463

Visteon Corporation
One Village Center Drive
Van Buren Township, MI 48111
(313) 755-2800

NAICS		423120
Employees		45,000
Revenue	(mil)	$11,418.00
Income	(mil)	($163.00)
Assets	(mil)	$6,938.00
Liability	(mil)	$7,126.00

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service affirmed its Caa2 rating on Visteon Corp.'s unsecured notes, shelf filings for unsecured, shelf filings for subordinated, and shelf filings for preferred. The ratings outlook was changed to negative from stable. Moody's said the negative outlook incorporates current views on the Company's prospective leverage, coverage ratios, and lack of free cash flow generation. The rating agency also considers the Company's exposure to a challenging automotive environment and the potential which any adverse industry developments may have to cause further deterioration in the Company's financial metrics.

Intellectual Property: The Company owns significant intellectual property, including a large number of patents, copyrights, proprietary tools and technologies and trade secrets and is involved in numerous licensing arrangements. The Company's general policy is to apply for patents on an ongoing basis, in appropriate countries, on its patentable developments which are considered to have commercial significance. The Company also views its name and mark as significant to its business as a whole. In addition, the Company holds rights in a number of other trade names and marks applicable to certain of its businesses and products that it views as important to such businesses and products. [SEC Filing 10-K 02-28-07]

Description: The Company supplies automotive systems, modules and components to vehicle manufacturers and the automotive aftermarket.

Officers: Michael F. Johnston (Chair & CEO); Donald J. Stebbins (Pres. & COO); James F. Palmer (EVP & CFO); John Donofrio (SVP & Gen. Counsel); John F. Kill (SVP); Robert Pallash (SVP); Dorothy L. Stephenson (SVP-HR); William G. Quigley III (SVP, Controller, & Chief Acctg. Officer)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol VC; NYSE;
129,013,936 common shares outstanding as of February 23, 2007.
8.25% notes due August 1, 2010; 7% senior notes due March 10, 2014.

Return to top

Prospector Profile 07.0464

Voice Mobility International, Inc.
100 - 4190 Lougheed Highway
Burnaby, British Columbia V5C 6A8
Canada
(604) 482-0000

NAICS		517212
Employees		14
Revenue	(mil)	$0.09
Income	(mil)	($3.30)
Assets	(mil)	$3.90
Liability	(mil)	$40.43

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP expressed substantial doubt about Voice Mobility International, Inc.'s ability to continue as a going concern after auditing the company's financial statements for the years ended Dec. 31, 2006, and 2005. The auditing firm pointed to the company's recurring net losses and shareholders' deficiency.

Intellectual Property: The Company does not have any registered patents, trademarks, or copyrights but relies on trade secrets to protect intellectual property. The Company executes confidentiality and non-disclosure agreements with employees and limit access to and distribution of proprietary information. The Company does not intend to apply for patents on its products. Management believes that the patent application process in many countries would be time-consuming and expensive and any patent protection may be out of date by the time the patent is granted. [SEC Filing 10-KSB 03-23-07]

Description: The Company is engaged in the enhanced and multimedia messaging area of the telecommunications market.

Officers: Gary Donahee (Chair); James J. Hutton (Pres. & Dir.); Randy G. Buchamer (CEO & Dir.); Morgan Sturdy (Dir.); Donald A. Calder (Dir.); Robert E. Neal (Dir.); David Raffa (Dir.); Kenneth R. Miller (Dir.); Gerry Butters (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol VMY.TO; Toronto Stock Exchange; 56,405,696 common shares outstanding as of March 1, 2007.

Return to top